Abdelazem Khaled
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Abdelazem Khaled has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
Abdulrahman Mohamed Tantawy
Faculty of Medicine, Zagazig University, Zagazig, Sharkia, Egypt
1 shared publication- Ahmed Elshahat
Faculty of Medicine, Al-Azhar University, Cairo, Egypt
1 shared publication Ahmed Hamdy Gheith
Faculty of Medicine, Zagazig University, Zagazig, Sharkia, Egypt
1 shared publication- Ahmed Mostafa Amin
Faculty of Medicine, Al-Azhar University, Cairo, Egypt
1 shared publication - Ahmed Osman Mohamed
Department of Pharmaceutical Microbiology, Faculty of Pharmacy, International University of Africa, Khartoum P.O. Box 2469, Sudan
1 shared publication - Ammar Mektebi
Negida Research Academy, Arlington, Virginia, USA
1 shared publication
Latest Publications
- 19 January 2026
- Published by BMJ in Archives of Disease in Childhood - Fetal and Neonatal Edition
- Vol. 111 (4) , F352-F359
Effect of different feeding approaches on growth, neonatal morbidities, mortality and neurodevelopmental outcome in preterm infants: a systematic review and network meta-analysis
Objective: To compare feeding strategies on preterm infants’ growth during hospitalisation, neonatal morbidities, mortality and neurodevelopmental outcome (NDO) at 18–26 months corrected age. Methods: We followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension statement for network meta-analysis . We searched five medical databases for randomised controlled trials comparing different feeding approaches in preterm infants and their effects on growth, neonatal morbidities, mortality and NDO. The Cochrane Collaboration’s tool was used to assess the risk of bias. We used a random-effects model. Pooled mean differences (MD) or risk ratios with 95% CIs were calculated. Results: Ninety-five studies (9663 infants) were included. Human milk (HM) with bovine milk fortifier (BMF) (adjusted according to blood urea nitrogen) achieved the best length increment (MD=0.56 cm/week; 95% CI 0.19 to 0.93). Notably, HM+BMF (3.5 gm/kg/d protein) showed the best head circumference growth (MD 0.46 cm/week; 95% CI 0.10 to 0.81) but no significant difference in weight gain. There were no significant differences in neonatal morbidities/mortality. While MOM|+PTF (supp) displayed significantly lower NDO delay in the domain of mild cognitive delay. Conclusion: Overall, there is a lack of strong evidence to support a specific enteral feeding strategy and further high-quality research is required. Targeted HM fortification appears to improve head growth, while adjusted fortification enhances length. Given the significant inconsistency detected, which may compromise the reliability of the network estimates, these results must be interpreted carefully.
- 19 January 2026
- Published by BMJ in Archives of Disease in Childhood - Fetal and Neonatal Edition
- Vol. 111 (4) , F352-F359
Effect of different feeding approaches on growth, neonatal morbidities, mortality and neurodevelopmental outcome in preterm infants: a systematic review and network meta-analysis
Objective: To compare feeding strategies on preterm infants’ growth during hospitalisation, neonatal morbidities, mortality and neurodevelopmental outcome (NDO) at 18–26 months corrected age. Methods: We followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension statement for network meta-analysis . We searched five medical databases for randomised controlled trials comparing different feeding approaches in preterm infants and their effects on growth, neonatal morbidities, mortality and NDO. The Cochrane Collaboration’s tool was used to assess the risk of bias. We used a random-effects model. Pooled mean differences (MD) or risk ratios with 95% CIs were calculated. Results: Ninety-five studies (9663 infants) were included. Human milk (HM) with bovine milk fortifier (BMF) (adjusted according to blood urea nitrogen) achieved the best length increment (MD=0.56 cm/week; 95% CI 0.19 to 0.93). Notably, HM+BMF (3.5 gm/kg/d protein) showed the best head circumference growth (MD 0.46 cm/week; 95% CI 0.10 to 0.81) but no significant difference in weight gain. There were no significant differences in neonatal morbidities/mortality. While MOM|+PTF (supp) displayed significantly lower NDO delay in the domain of mild cognitive delay. Conclusion: Overall, there is a lack of strong evidence to support a specific enteral feeding strategy and further high-quality research is required. Targeted HM fortification appears to improve head growth, while adjusted fortification enhances length. Given the significant inconsistency detected, which may compromise the reliability of the network estimates, these results must be interpreted carefully.
- Open Access
- 7 April 2022
- Published by Egyptian Knowledge Bank in Zagazig University Medical Journal
Mechanism of actions of some common toxic agents causing toxic cardiomyopathy
Background: Toxic cardiomyopathy is related to heart failure in many cases and may lead to death. We focused on the mechanisms by which some common toxic agents cause cardiomyopathy. We searched in articles, case reports, experimental and clinical studies on this topicOur results have shown that the heart or the cardiovascular system is one of the most affected systems by toxic agents. We summarized studies which mentioned some common cause such as; "Anti-cancer drugs", "Anti-diabetic drugs", "Cocaine", "Ethanol", "Heavy Metals", and "Digitalis drugs” and their mechanism of action inducing cardiotoxicity.. We concluded that mechanisms underlying toxic cardiomyopathy are complicated and variable. However, they generally include disruption of cell bioenergetics and intracellular calcium handling. It is also involved in: production of reactive oxygen species (ROS), development of oxidative stress and apoptosis induction.Conclusion: Toxic agents have a very harmful effect on the heart producing cardiomyopathy and heart failure. A lot of drugs and environmental toxins can produce cardiotoxicity including; anti-cancer drugs, anti-diabetic drugs, cocaine, ethanol, CO, and heavy metals their mechanisms of action are complicated and included many factors.
- 7 April 2022
- Published by Egyptian Knowledge Bank in Zagazig University Medical Journal
Open AccessMechanism of actions of some common toxic agents causing toxic cardiomyopathy
Background: Toxic cardiomyopathy is related to heart failure in many cases and may lead to death. We focused on the mechanisms by which some common toxic agents cause cardiomyopathy. We searched in articles, case reports, experimental and clinical studies on this topicOur results have shown that the heart or the cardiovascular system is one of the most affected systems by toxic agents. We summarized studies which mentioned some common cause such as; "Anti-cancer drugs", "Anti-diabetic drugs", "Cocaine", "Ethanol", "Heavy Metals", and "Digitalis drugs” and their mechanism of action inducing cardiotoxicity.. We concluded that mechanisms underlying toxic cardiomyopathy are complicated and variable. However, they generally include disruption of cell bioenergetics and intracellular calcium handling. It is also involved in: production of reactive oxygen species (ROS), development of oxidative stress and apoptosis induction.Conclusion: Toxic agents have a very harmful effect on the heart producing cardiomyopathy and heart failure. A lot of drugs and environmental toxins can produce cardiotoxicity including; anti-cancer drugs, anti-diabetic drugs, cocaine, ethanol, CO, and heavy metals their mechanisms of action are complicated and included many factors.